Everett Collection / Shutterstock.com
Two of Mexico’s authorities manage the patent-MA process for patenting drugs, but it is not always a simple matter, as Xavier Hadad reports.
Over the course of time, and in an increasingly globalised world, the pharmaceutical industry has gained strength and a stronger identity because it integrates two main functions in its structure: ensuring the health of the population in each state or country, and protecting and maximising scientific and technological developments to justify the introduction of a medicine to the population.
Ensuring the fundamental rights of inventors to recover the money and time invested in research to invent new products through patents is also necessary. Even so, there have been several problems for companies known to be innovative and the ones that are known for their generic medicines.
Additionally, there is a regulatory process in each country that does not always go hand in hand with the patent system, which makes it necessary to seek amendments to local laws to achieve a safe and effective governance system.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on email@example.com.
patents, medicine, IMPI, pharmaceuticals